Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
1 other identifier
interventional
120
1 country
1
Brief Summary
The purpose of this study is to see whether patients triggered with only human Chorion Gonadotropin (hCG) have higher number of Metaphase II oocytes (MII) and implantation rate than patients triggered with hCG combined with Gonadotropin Releasing Hormone (GnRH) agonist.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Nov 2011
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2011
CompletedFirst Submitted
Initial submission to the registry
May 4, 2012
CompletedFirst Posted
Study publicly available on registry
May 30, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedResults Posted
Study results publicly available
February 19, 2015
CompletedFebruary 19, 2015
February 1, 2015
2.1 years
May 4, 2012
December 30, 2013
February 3, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MII Oocytes
the number of mature oocytes retrieved
3 weeks
Secondary Outcomes (2)
Pregnancy Rate
12 weeks
Patients With Cryopreserved Embryos
4 weeks
Study Arms (2)
hCG
ACTIVE COMPARATOR5000 IU Pregnyl SC
hCG and GnRH agonist
ACTIVE COMPARATOR5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
Interventions
Eligibility Criteria
You may qualify if:
- Intra-cytoplasmic sperm injection (ICSI) patients below 38 years
- ,2 or 3 rd IVF-cycle
You may not qualify if:
- polycystic ovary syndrome (PCOS) patients
- patients with endocrinological diseases or problems
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AZ Jan Palfijn Gentlead
- Onze Lieve Vrouw Hospitalcollaborator
Study Sites (1)
A Z Jan Palfijn
Ghent, Oost-vlaanderen, 9000, Belgium
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- dr.Decleer Wim
- Organization
- AZ JAN PALFIJN
Study Officials
- PRINCIPAL INVESTIGATOR
Wim Decleer, gynacologist
IVF Centrum Jan Palfijn Gent
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- gynaecologist
Study Record Dates
First Submitted
May 4, 2012
First Posted
May 30, 2012
Study Start
November 1, 2011
Primary Completion
December 1, 2013
Study Completion
December 1, 2013
Last Updated
February 19, 2015
Results First Posted
February 19, 2015
Record last verified: 2015-02